Bots, editor, reviewer, Administrators
13,951
edits
No edit summary |
No edit summary |
||
Line 211: | Line 211: | ||
"title" : "Effects of combination lipid therapy in type 2 diabetes mellitus", | "title" : "Effects of combination lipid therapy in type 2 diabetes mellitus", | ||
"pmid" : "20228404" | "pmid" : "20228404" | ||
}, | |||
{ | |||
"timestamp" : "2024-02-22T19:23:07Z", | |||
"briefDesignDescription" : "Empiric cefepime vs. pip-tazo for infection", | |||
"fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/2810592", | |||
"pageid" : 5478, | |||
"pdfurl" : null, | |||
"trainingLevel" : "Resident", | |||
"citation" : "Qian E, <i>et al</i>. \"Cefepime vs. piperacillin-tazobactam in adults hospitalized with acute infection\". <i>JAMA</i>. 2023. 330(16):1557-1567.", | |||
"subspecialties" : "Infectious Disease;Critical Care;Emergency Medicine", | |||
"expansion" : "Antibiotic Choice on Renal Outcomes", | |||
"statusUsableDate" : "2024-02-22", | |||
"briefResultsDescription" : "Similar rates of AKI; cefepime causes more CNS toxicity", | |||
"published" : "2023-10-14", | |||
"pageName" : "ACORN", | |||
"diseases" : "Infection", | |||
"abbreviation" : "ACORN", | |||
"title" : "Cefepime vs. piperacillin-tazobactam in adults hospitalized with acute infection", | |||
"pmid" : "37837651" | |||
}, | }, | ||
{ | { | ||
Line 9,046: | Line 9,065: | ||
"title" : "A Comparison of Four Treatments for Generalized Convulsive Status Epilepticus", | "title" : "A Comparison of Four Treatments for Generalized Convulsive Status Epilepticus", | ||
"pmid" : "9738086" | "pmid" : "9738086" | ||
}, | |||
{ | |||
"timestamp" : "2024-02-22T20:28:09Z", | |||
"briefDesignDescription" : "Omega-3 FA for CV and cancer prevention", | |||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1811403", | |||
"pageid" : 4179, | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1811403", | |||
"trainingLevel" : "resident", | |||
"citation" : "Manson JE, <i>et al</i>. \"Marine n-3 fatty acids and prevention of cardiovascular disease and cancer\". <i>The New England Journal of Medicine</i>. 2019. 2019(380):1.", | |||
"subspecialties" : "Cardiology;Oncology", | |||
"expansion" : "Vitamin D and Omega-3 Trial", | |||
"statusUsableDate" : "2024-02-22", | |||
"briefResultsDescription" : "Omega-3 FA did not lower CV or cancer events", | |||
"published" : "2019-01-03", | |||
"pageName" : "VITAL (Omega-3 arm)", | |||
"diseases" : "Cardiovascular Disease;Cancer", | |||
"abbreviation" : "VITAL", | |||
"title" : "Marine n-3 fatty acids and prevention of cardiovascular disease and cancer", | |||
"pmid" : "30415637" | |||
}, | }, | ||
{ | { |